Analysen des hämatopoetischen Chimärismus - TOBIAS-lib ...

(106) van der Velden V, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse
MJ, Hahlen K, Kamps WA, van Wering ER, van Dongen JJ. Minimal
residual disease levels in bone marrow and peripheral blood are
comperable in children with T-cell acutelymphoblastic leukemia (ALL), but
not in precursor-B-ALL. Leukemia 2002; 16(8):1432-1436.
(107) van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Khan PM, Vossen
JM. Mixed T-lymphoid chimerism after allogeneic bone marrow
transplantation for hematologic malignancies of children is not correlated
with relapse. Blood 1993; 82(6):1921-1928.
(108) van Leeuwen JE, van Tol MJ, Joosten AM, Wijnen JT, Verweij PJ, Khan
PM, Vossen JM. Persistence of host-type hematopoiesis after allogeneic
bone marrow transplantation for leukemia is significantly related to the
recipient's age and/or the conditioning regimen, but it is not associated with
an increased risk of relapse. Blood 1994; 83(10):3059-3067.
(109) Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW,
Tilanus MG, de Weger RA. Donor leukocyte infusions for recurrent
hematologic malignancies after allogeneic bone marrow transplantation:
impact of infused and residual donor T cells. Bone Marrow Transplant
1998; 22(11):1057-1063.
(110) Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD,
Storb R. Antileukemic effect of graft-versus-host disease in human
recipients of allogeneic marrow grafts. N Engl J Med 1979; 300:1068-73.
(111) Wessmann M, Ruutu T, Volin L, Knuutila S. In situ hybridization using a Yspecific
probe - a sensitive method for distinguishing residual male
recipient cells from female donor cells in bone marrow transplantation.
Bone Marrow Transplant 1989; 4:283-286.
(112) Zeiser R, Spyridonidis A, Wasch R, Ihorst G, Grullich C, Bertz H, Finke J.
Evaluation of immunomodulatory treatment based on conventional and
lineage-specific chimerism analysis in patients with myeloid malignancies
after myeloablative allogeneic hematopoietic cell transplantation. Leukemia
2005; 19(5):814-821.
(113) Zetterquist H, Mattsson J, Uzunel M, Nasman-Bjork I, Svenberg P,
Tammik L, Bayat G, Winiarski J, Ringden O. Mixed chimerism in the B cell
lineage is a rapid and sensitive indicator of minimal residual disease in
bone marrow transplant recipients with pre-B cell acute lymphoblastic
leukemia. Bone Marrow Transplant 2000; 25(8):843-851.
86